The data suggest that conventional chemotherapy combined with stromal component-targeting therapeutics can induce tumour responses more dramatically than chemotherapy alone, and the efficacy of a SPINK1-specific monoclonal antibody is even superior to cetuximab, an anti-EGFR antibody widely used to restrain EGFR+ neoplastic cell expansion by promoting their apoptosis in multiple cancer types39. The gene discussed is EGFR; the disease is neoplasm.